Pharmaceutical

Request for TOC Request for Sample
BUY NOW

North America Pingueculum Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical | Published Report | Nov 2022 | North America | 350 Pages | No of Tables: 92 | No of Figures: 47

Report Description

North America Pingueculum Drugs Market, By Treatment (Artificial Tears /Topical Lubricants, Steroid Eye Drops, Non-steroidal Anti Inflammatory Drops and Others), Formulation Type (Eye Drops, Eye Ointments and Others), Mode of Purchase (Prescription, Over the Counter (OTC)), Drug Type (Branded and Generics), Population Type (Geriatric and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) - Industry Trends and Forecast to 2029.

Get Exclusive Sample Copy of this Report Here

North America Pingueculum Drugs Market Analysis and Insights

A pingueculum is a typical conjunctival growth that is not malignant. The risk factors for the progression of pinguecula include exposure to ultraviolet light, trauma, wind, dust, and sand, working outdoors for a long duration, and advancing age. UV exposure is strongly linked to the occurrence of pterygia.

Get Exclusive Sample Copy of this Report Here

Get Exclusive Sample Copy of this Report Here

North America pingueculum drugs market report provides details of market share, new developments and product pipeline analysis, the impact of domestic and localized market players, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal.

Data Bridge Market Research analyses that the North America pingueculum drugs market will grow at a CAGR of 6.8% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customisale to 2014-2019)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Treatment (Artificial Tears /Topical Lubricants, Steroid Eye Drops, Non-steroidal Anti Inflammatory Drops and Others), Formulation Type (Eye Drops, Eye Ointments and Others), Mode of Purchase (Prescription, Over the Counter (OTC)), Drug Type (Branded and Generics), Population Type (Geriatric and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)

Countries Covered

U.S., Canada, Mexico

Market Players Covered

AbbVie Inc., Amneal Pharmaceuticals LLC., Spectra Vision Care, SAGER PHARMA, Maya Biotech Private Limited, Novartis AG, Akorn Operating Company LLC, Théa Laboratories, OASIS Medical, Similasan Corporation, Bausch & Lomb Incorporated, Prestige Consumer Healthcare, Inc., Alcon Inc., Wellona Pharma, Johnson & Johnson Vision Care, Inc., EYERIS VISIONCARE Pvt. Ltd., Sylentis , Zydus Group, Bayer AG, Santen Pharmaceutical Co., Ltd

Market Definition

A pingueculum is a typical conjunctival growth that is not malignant. This is the transparent, delicate tissue that encircles the eye's white region (sclera). Pinguecula word is derived from the Latin word pinguis, which means "fat" or "grease." The growth occurs in the part of the conjunctiva that is exposed when the eye is open. The risk factors for the progression of pinguecula include exposure to ultraviolet light, trauma, wind, dust and sand, working outdoors for a long duration and advancing age. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could simply be due to a higher rate of UV exposure. It appears as a tiny, yellowish bump on the conjunctiva close to the cornea. It may emerge on either side of the cornea.

North America Pingueculum Drugs Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below

  • Rising prevalence of pinguecula disorders and ocular pains

In 2020, according to the published article "Prevalence and associated factors of pinguecula in Western Turkey" by ULAKBİM Journal Systems, the study included 1443 individuals over the age of 20 years of Western Turkey, where it was found that 52.5% of people had pinguecula and out of that 52.5%, the prevalence of pinguecula was higher in males (58.4%), as compared to females (46.8%).

The prevalence of pinguecula disease keeps showing a surge in growth as several environmental and external factors worldwide. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Thus, the rising prevalence of pinguecula disorder and ocular pain is expected to drive the North America pingueculum drugs market in the forecast period.

  • Rise in chronic UV radiation exposure due to ozone defect

In 2019, according to the published journal by "the Association for Research in Vision and Ophthalmology," it was stated that early pinguecula was found to have a prevalence of 39.5% in the temporal conjunctiva and 43.9% in the nasal conjunctiva respectively. That the reported amount of time spent on outdoor activities was 19.6% and 16.1% for less than 2 hours, 44.7% and 52.2% for 4 to 6 hours, respectively and 75.0% in both fields for more than 6 hours, indicates a positive correlation between the prevalence of pinguecula and the amount of time spent on outdoor activities and UV radiation exposure.

There is a correlation between increased exposure to UV and a higher prevalence of pinguecula. This demonstrates that there is a connection between the prevalence of pinguecula and exposure to sunlight. The ozone layer defect is also leading to an increase in the exposure of UV exposure which is increasing the prevalence of pinguecula disorder. Thus, it is expected to drive The North America pingueculum drugs market growth.

  • Initiatives and plans to lessen the prevalence of eye illnesses

In 2020, The VISION 2020: The Right to Sight initiative was introduced in 1999 by the World Health Organization (WHO), Geneva, Switzerland and the International Agency for the Prevention of Blindness (IAPB), London, England. The Europe initiative VISION2020 seeks to end avoidable blindness by 2020 and focuses on the main causes of avoidable visual impairment.

According to the article by CDC (Centres for disease control and prevention), in 2022, through Vision Health Initiative (VHI) and diverse stakeholders, CDC initiated a coordinated national public health framework to prevent blindness and vision impairment.

The initiatives and plans are working as an opportunity for the market. Hence, initiatives and plans to lessen the prevalence of eye illness are expected to act as an opportunity for the growth of the North America pingueculum drugs market.

Restraints/Challenges

  • Adverse effects of steroid eye drops

Ophthalmologists or optometrists are recommended by patients with mild to severe pinguecula for a thorough examination and prompt treatment. Most often, local tropical steroids, tropical immune modulators, lubricating ointment, gel, or drops are used to treat them.

Prednisolone is the topical steroid that is most frequently used to treat ocular pain. The prednisolone acetate ophthalmic suspension has below mentioned common adverse effects:

  • Eyes sting, burn, or itch for one to two minutes after using this medicine
  • Vision temporarily obscured
  • Increased light sensitivity
  • Visual alterations
  • Experiencing a foreign object in your eyes
  • Allergic responses

Lack of healthcare facilities for eye treatment

As per IntechOpen 2020 report, the prevalence of blindness and ocular disorders in high-income countries is 0.3 per 1000 people, but in low-income countries, the estimation is 1.5 per 1000. This shows the unmet need for ophthalmology care in low-income countries

Another major problem in low-income countries is the lack of awareness regarding ocular pain and other disorders. Many research studies report the high requirement of low-income countries for eye health care and their unmet needs are still gaining attention among many healthcare organizations. Hence, the poor healthcare facility for eye treatments in low and middle-income countries may act as restraints for the growth of the North America pingueculum drugs market.

Post-COVID-19 Impact on the North America Pingueculum Drugs Market

COVID-19 has negatively affected the market. Lockdowns and isolation during the pandemic complicate disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.

 Recent Developments

  • In May 2022, Alcon announced the acquisition of EYSUVIS (loteprednol etabonate suspension) pharmaceutical eye drop from Kala Pharmaceuticals, Inc. The acquisition will complement the company's Systane family of eye drops which includes preservative free formulations among others
  • In September 2022, Johnson & Johnson Vision Care, Inc. announced the launch of its new innovation of Acuvue Oasys Max–day contact lenses and its multifocal contact lenses for presbyopia. Additionally, these new contact lenses are with the new technology to meet the digitally intense lifestyle

North America Pingueculum Drugs Market Scope

The North America pingueculum drugs market is categorized into seven notable segments based on drug type, treatment, formulation, mode of purchase, population type, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Artificial Tears/Topical Lubricants
  • Steroid Eye Drops
  • Non-steroidal Eye Drops
  • Others

Based on treatment, the North America pingueculum drugs market is segmented into artificial tears/topical lubricants, steroid eye drops, non-steroidal eye drops and others.

Formulation Type

  • Eye Drops
  • Eye Ointments
  • Others

Based on formulation, the North America pingueculum drugs market is segmented into eye drops, eye ointments and others.

Mode of Purchase

  • Prescription
  • Over the Counter (OTC)

Based on mode of purchase, the North America pingueculum drugs market is segmented into prescription and over the counter (OTC).

Drug Type

  • Branded
  • Generics

Based on population type, the North America pingueculum drugs market is segmented into branded and generics.

Population Type

  • Geriatric
  • Adults

Based on population type, the North America pingueculum drugs market is segmented into geriatric and adults.

End User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

Based on end user, the North America pingueculum drugs market is segmented into hospitals, specialty clinics, home healthcare and others.

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

Get Exclusive Sample Copy of this Report Here

Based on the distribution channel, the North America pingueculum drugs market is segmented into retail pharmacies, hospital pharmacies, online pharmacies and others.

Pingueculum Drug Market Regional Analysis/Insights

The North America pingueculum drugs market is analyzed and market size insights and trends are provided by country, drug type, treatment, formulation, mode of purchase, population type, end user and distribution channel as referenced above.

The countries covered in the North America pingueculum drugs market report are U.S., Canada, and Mexico.

The U.S. is expected to dominate the North America pingueculum drugs market because of government initiatives to aware the population and rising awareness among the population about the disease.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and the challenges faced due to high competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Pingueculum Drugs Market Share Analysis

North America pingueculum drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North American presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to North America pingueculum drugs market.

Some of the major players operating in the North America pingueculum drugs market are AbbVie Inc., Amneal Pharmaceuticals LLC., Novartis AG, Akorn Operating Company LLC, Théa Laboratories, OASIS Medical, Similasan Corporation, Bausch & Lomb Incorporated, Prestige Consumer Healthcare, Inc., Alcon Inc., Wellona Pharma, Johnson & Johnson Vision Care, Inc., Bayer AG, Santen Pharmaceutical Co., Ltd., Zydus Group, among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, North America Vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 TREATMENT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END-USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 EPIDERMIOLOGY

4.2 PESTEL ANALYSIS

4.3 PORTER’S FIVE FORCES

4.4 PIPELINE ANALYSIS FOR THE NORTH AMERICA PINGUECULUM DRUGS MARKET

4.5 INDUSTRIAL INSIGHTS:

4.6 CONCLUSION:

5 NORTH AMERICA PINGUECULUM DRUGS MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF PINGUECELA DISORDERS AND OCULAR PAINS

6.1.2 RISE IN THE CHRONIC UV RADIATION EXPOSURE DUE TO OZONE DEFECT

6.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES

6.1.4 RISING OPHTHALMIC EMERGENCIES IN THE GERIATRIC PATIENT

6.2 RESTRAINTS

6.2.1 STRINGENT RULES & REGULATIONS

6.2.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT

6.3 OPPORTUNITIES

6.3.1 INITIATIVES AND PLANS TO LESSEN THE PREVALENCE OF EYE ILLNESSES

6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

6.3.3 INCREASE IN HEALTHCARE SPENDING AND ACCESSIBLE INCOME

6.4 CHALLENGES

6.4.1 ADVERSE EFFECTS OF STEROID EYE DROPS

6.4.2 LACK OF SKILLED OPHTHALMOLOGISTS

7 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS

7.2.1 DEMULCENT

7.2.2 EMOLLIENTS

7.3 STEROID EYE DROPS

7.3.1 KETONE STEROIDS

7.3.1.1 PREDNISOLONE

7.3.1.2 DEXAMETHASONE

7.3.1.3 FLUROMETHOLONE

7.3.1.4 MEDRYSONE

7.3.1.5 RIMEXOLONE

7.3.1.6 OTHERS

7.3.2 ESTER STEROID (LOTERPREDNOL)

7.4 NON-STEROIDAL ANTI-INFLAMMATORY DROPS

7.5 OTHERS

8 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY FORMULATION

8.1 OVERVIEW

8.2 EYE DROPS

8.2.1 EYE DROPS WITH PRESERVATIVES

8.2.2 PRESERVATIVE-FREE EYE DROPS

8.3 EYE OINTMENTS

8.3.1 WITH PRESERVATIVES

8.3.2 PRESERVATIVE-FREE

8.3.3 OTHERS

8.4 OTHERS

9 NORTH AMERICA PINGUECULUM DRUGS MARKET, MODE OF PURCHASE

9.1 OVERVIEW

9.2 PRESCRIPTION

9.3 OVER THE COUNTER (OTC)

10 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE

10.1 OVERVIEW

10.2 BRANDED

10.3 GENERICS

11 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE

11.1 OVERVIEW

11.2 GERIATRIC

11.2.1 MALE

11.2.2 FEMALE

11.3 ADULTS

11.3.1 MALE

11.3.2 FEMALE

12 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 SPECIALTY CLINICS

12.4 HOME HEALTHCARE

12.5 OTHERS

13 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 RETAIL PHARMACIES

13.3 HOSPITAL PHARMACIES

13.4 ONLINE PHARMACIES

13.5 OTHERS

14 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY REGION

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 MEXICO

14.1.3 CANADA

15 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 ALCON INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 ABBVIE INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 BAUSCH & LOMB INCORPORATED

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 BAYER AG

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENTS

17.5 JOHNSON & JOHNSON VISION CARE, INC.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 AKORN OPERATING COMPANY LLC

17.6.1 COMPANY SNAPSHOT

17.6.2 . PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 AMNEAL PHARMACEUTICALS LLC.

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENTS

17.8 EYERIS VISIONCARE PVT. LTD.

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENTS

17.9 LABORATOIRES THÉA

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 MAYA BIOTECH PRIVATE LIMITED

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENTS

17.11 NOVARTIS AG

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 OASIS MEDICAL, INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.13 PRESTIGE CONSUMER HEALTHCARE, INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 PRODUCT PORTFOLIO

17.13.3 RECENT DEVELOPMENT

17.14 SAGER PHARMA

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENTS

17.15 SANTEN PHARMACEUTICAL CO., LTD.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENTS

17.16 SIMILASAN CORPORATION

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENTS

17.17 SPECTRA VISION CARE

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENTS

17.18 SYLENTIS

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENTS

17.19 WELLONA PHARMA

17.19.1 COMPANY SNAPSHOT

17.19.2 PRODUCT PORTFOLIO

17.19.3 RECENT DEVELOPMENTS

17.2 ZYDUS GROUP

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 2 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA PRESCRIPTION IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA OVER THE COUNTER (OTC) IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA BRANDED IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA GENERICS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA ADULTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA HOSPITALS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA SPECIALTY CLINICS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA HOME HEALTHCARE IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA RETAIL PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA HOSPITAL PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA ONLINE PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 51 U.S. PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 U.S. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 U.S. STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 U.S. KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 U.S. PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 56 U.S. EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 57 U.S. EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 58 U.S. PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 59 U.S. PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)

TABLE 60 U.S. PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 61 U.S. GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 62 U.S. ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 63 U.S. PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 U.S. PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 MEXICO PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 MEXICO ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 MEXICO STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 MEXICO KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 MEXICO PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 70 MEXICO EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 71 MEXICO EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 72 MEXICO PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 73 MEXICO PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)

TABLE 74 MEXICO PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 75 MEXICO GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 76 MEXICO ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 77 MEXICO PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 78 MEXICO PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 79 CANADA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 CANADA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 CANADA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 CANADA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 83 CANADA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 84 CANADA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 85 CANADA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 86 CANADA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 87 CANADA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)

TABLE 88 CANADA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 89 CANADA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 90 CANADA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 91 CANADA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 92 CANADA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA PINGUECULUM DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA PINGUECULUM DRUGS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA PINGUECULUM DRUGS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA PINGUECULUM DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA PINGUECULUM DRUGS MARKET: DBMR POSITION GRID

FIGURE 8 NORTH AMERICA PINGUECULUM DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA PINGUECULUM DRUGS MARKET: END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND THE RISE IN THE GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA PINGUECULUM DRUGS MARKET GROWTH FROM 2022 TO 2029

FIGURE 12 ARTIFICIAL TEARS/TOPICAL LUBRICANTS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET FROM 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET

FIGURE 14 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, 2021

FIGURE 15 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 18 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, 2021

FIGURE 19 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, 2022-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, LIFELINE CURVE

FIGURE 22 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2021

FIGURE 23 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 26 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2021

FIGURE 27 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2021

FIGURE 31 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 34 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, 2021

FIGURE 35 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 39 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 40 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 41 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 NORTH AMERICA PINGUECULUM DRUGS MARKET: SNAPSHOT (2021)

FIGURE 43 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2021)

FIGURE 44 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT (2022-2029)

FIGURE 47 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY SHARE 2021 (%)

View Infographics

FIGURE 1 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA PINGUECULUM DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA PINGUECULUM DRUGS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA PINGUECULUM DRUGS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA PINGUECULUM DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA PINGUECULUM DRUGS MARKET: DBMR POSITION GRID

FIGURE 8 NORTH AMERICA PINGUECULUM DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA PINGUECULUM DRUGS MARKET: END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND THE RISE IN THE GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA PINGUECULUM DRUGS MARKET GROWTH FROM 2022 TO 2029

FIGURE 12 ARTIFICIAL TEARS/TOPICAL LUBRICANTS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET FROM 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET

FIGURE 14 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, 2021

FIGURE 15 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 18 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, 2021

FIGURE 19 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, 2022-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, LIFELINE CURVE

FIGURE 22 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2021

FIGURE 23 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 26 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2021

FIGURE 27 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2021

FIGURE 31 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 34 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, 2021

FIGURE 35 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 39 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 40 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 41 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 NORTH AMERICA PINGUECULUM DRUGS MARKET: SNAPSHOT (2021)

FIGURE 43 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2021)

FIGURE 44 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT (2022-2029)

FIGURE 47 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY SHARE 2021 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19